Tag
46 posts tagged “Build muscle”.
A measured, harm-reduction look at MK-677, what it actually does to GH and IGF-1, and the daily signals and bloodwork worth watching.
A neutral, harm-reduction look at ostarine, why it is the mildest of the SARMs, and what to monitor given it still suppresses natural hormones.
A harm-reduction look at ligandrol, why its strength comes with strong hormonal suppression, and the monitoring that actually matters.
A harm-reduction look at RAD-140, its strong anabolic effect, the reported liver-injury signals, and what to monitor closely.
A harm-reduction look at andarine, its use in cutting phases, and the reversible vision side effect that sets it apart from other SARMs.
A harm-reduction look at YK-11, a steroidal compound sold as a SARM with myostatin-inhibition claims, and why the human evidence is essentially absent.
A harm-reduction look at bimagrumab, an investigational antibody that lowers fat while preserving or adding muscle, studied with semaglutide.
A harm-reduction look at methasterone, a potent and markedly hepatotoxic oral steroid, and the monitoring that matters most if someone has already decided to use it.
A harm-reduction look at trestolone, a very potent nandrolone-like injectable that is strongly suppressive and aromatizes to a potent estrogen, and what to monitor.
A harm-reduction look at dihydroboldenone, a non-aromatizing injectable anabolic notorious for post-injection pain, and the monitoring worth doing.
A measured, harm-reduction look at testosterone undecanoate in both its very long-ester injectable and oral forms, and the bloodwork that actually matters.
A cautious, harm-reduction look at follistatin and ACE-031, why the human evidence is thin, and what to log if you use them anyway.
A measured, harm-reduction look at testosterone enanthate, what to monitor on TRT or a cycle, and the bloodwork that actually matters.
Cypionate behaves almost identically to enanthate. Here is what to monitor, the bloodwork that matters, and the mistakes to avoid.
Propionate clears fast, which means frequent injections and sharper fluctuations. Here is what that changes about tracking.
A four-ester testosterone blend with a tricky release curve. Why the mixed esters complicate tracking and what to monitor.
A long-ester 19-nortestosterone with a real medical history and serious suppression. What to monitor, including the things people miss.
NPP is nandrolone on a faster ester. Same compound, same risks, more frequent injections. What to track.
A potent 19-nor anabolic with a heavy side-effect load. This is a harm-reduction tracking guide, not an endorsement.
Same potent, high-risk compound as the enanthate version, on a short ester. What the faster clearance changes for tracking.
A long-acting veterinary steroid sometimes used by humans. What it does, the slow timeline, and what to monitor.
A DHT-derived anabolic associated with cutting and "hardening." What that means, what it does not do, and what to monitor.
The longer-acting version of Masteron. Same DHT-derived profile, fewer injections, slower kinetics. What to track.
Often called gentle, but still suppressive and not risk-free. What "mild" actually means and what to monitor.
An oral with a real medical history and a gentle reputation - but real liver, lipid, and suppression concerns. What to monitor.
Fast mass and strength, heavy water retention, and real liver and blood-pressure costs. What to monitor on this classic oral.
A DHT-derived steroid known for a "dry" look - and for hammering cholesterol and joints. What to monitor closely.
Big, fast mass and red-cell effects with heavy liver, blood-pressure, and side-effect load. What to monitor carefully.
A non-aromatising oral known for steady lean gains and a long detection window. What to track and the liver and lipid costs.
Why insulin is the most dangerous peptide on the menu, and how serious users approach tracking when medically indicated.
A pragmatic tracking guide for MGF, the muscle-damage-responsive splice variant of IGF-1.
A practical tracking guide for the DAC version of CJC-1295, with weekly dosing rationale and IGF-1 expectations.
A pragmatic log structure for ipamorelin used on its own, separate from the common CJC-1295 stack.
How the short-acting GHRH analog works, why it mimics natural GH pulses, and what to track when using it.
What to know about using a pre-mixed CJC-1295/ipamorelin blend versus separate vials, and how it affects your tracking.
A tracking guide for sermorelin, the 29-amino-acid GHRH analog, with realistic expectations for sleep, recovery, and IGF-1 changes.
What PEG-MGF is, how PEGylation changes the dosing schedule versus regular MGF, and how that changes what you track and when.
The strongest of the older GHRPs has tradeoffs that show up fast. Here is how to track them.
A practical look at pre-mixed sermorelin/ipamorelin blends — the GHRH plus GHRP rationale and the tracking tradeoffs of using one syringe.
A short-acting IGF-1 variant used in research and bodybuilding circles. Here is how to track it honestly.
A careful tracking guide for recombinant human growth hormone, focused on what to monitor when using a prescription compound with real metabolic consequences.
A practical tracking guide for GHRP-2, a ghrelin mimetic often paired with GHRH analogs, with attention to cortisol and prolactin.
A practical tracking guide for GHRP-6, with attention to the strong hunger response and how it fits a bulking phase.
Long-acting IGF-1 analog with extended half-life. What to measure and what to watch out for.
Two growth-hormone-releasing peptides that are usually used together. How they differ, how protocols are structured, and what to track.
What tesamorelin is, how protocols are structured, what to measure if you want to evaluate effects on visceral fat, energy, and sleep.